EUVIMEDEUVIMED entdecken
Crossref

Alcohol Use Following GLP-1 Receptor Agonist Therapy in the Cooper Center Longitudinal Study

Tamanna Basri, Stephanie J Shea, Adam Brantley, Rahul Tharoor, Julia Chavez, Mehvish Khan, William G Burton, David Leonard, Carolyn E Barlow, Kerem Shuval, Laura F DeFina, E Sherwood Brown

Mayo Clinic Proceedings · 2026-07

DOI: 10.1016/j.mayocp.2026.07.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mayo Clinic Proceedings, 2026-07. Verfasst von Tamanna Basri und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To examine the association between glucagon-like peptide-1 receptor agonist (GLP-1RA) use and alcohol intake in a large cohort of outpatient adults who currently drink. PATIENTS AND METHODS: We conducted a retrospective analysis of 11,258 participants seen at the Cooper Clinic (Dallas, Texas) from January 2, 2008, to July 22, 2024, comparing changes in self-reported weekly alcohol intake between adults who were initiated on a GLP-1RA (n =256) versus a control group (n =11,002) that did not receive a GLP-1RA. A linear mixed-effects model was used to estimate changes in alcohol intake, adjusting for time between visits, age, sex, glucose level, and weight. RESULTS: The GLP-1RA treatment group had a greater reduction in weekly alcohol intake than the control group (-1.0 drinks/week; 95% CI -1.6 to -0.4; P =.002), which became non-significant after adjusting for weight change (P =.10). CONCLUSIONS: GLP-1RA treatment was associated with a reduction in alcohol intake. This effect was attenuated when controlling for weight loss. The findings suggest a reduction in alcohol use with GLP-1RAs that was related to a reduction in weight.

Schlagwörter

Stichwörter der Autor:innen

GLP-1 Receptor Agonistalcoholalcohol use disorderobesitysubstance use

Autor:innen und Institutionen

  • Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX.
  • Kenneth H Cooper Institute, Texas Tech University Health Sciences Center, Dallas, TX.
  • Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: Sherwood.Brown@UTSouthwestern.edu.

Zitieren

APA

Basri, T., Shea, S. J., Brantley, A., Tharoor, R., Chavez, J., Khan, M., Burton, W. G., Leonard, D., Barlow, C. E., Shuval, K., DeFina, L. F., & Brown, E. S. (2026). Alcohol Use Following GLP-1 Receptor Agonist Therapy in the Cooper Center Longitudinal Study. Mayo Clinic Proceedings. https://doi.org/10.1016/j.mayocp.2026.07.014

Vancouver

Basri T, Shea SJ, Brantley A, Tharoor R, Chavez J, Khan M, et al. Alcohol Use Following GLP-1 Receptor Agonist Therapy in the Cooper Center Longitudinal Study. Mayo Clinic Proceedings. 2026. doi:10.1016/j.mayocp.2026.07.014

BibTeX
@article{Basri2026,
  author = {Basri, Tamanna and Shea, Stephanie J and Brantley, Adam and Tharoor, Rahul and Chavez, Julia and Khan, Mehvish and Burton, William G and Leonard, David and Barlow, Carolyn E and Shuval, Kerem and DeFina, Laura F and Brown, E Sherwood},
  title = {Alcohol Use Following GLP-1 Receptor Agonist Therapy in the Cooper Center Longitudinal Study},
  journal = {Mayo Clinic Proceedings},
  year = {2026},
  doi = {10.1016/j.mayocp.2026.07.014}
}
Kostenlos starten →